Latest updates for Leoox
Fresh curated links around LEOOX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Lazard Enhanced Opportunities Portfolio Q2 2026 Commentary
- Portugal - Ovarense-inks-Leo-OBoyle-ex-Leeuwarden
- Leo – 9 month old male Cross-Breed
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Portugal - Ovarense-inks-Leo-OBoyle-ex-Leeuwarden
Ovarense-Gavex-Liga-Betclic-agreed-terms-with-26-year-old-American-forward-Leo-OBoyle-201cm-95kg-2000-college-Penn-State-for-new-2026-27-season-He-played-last-season-at-LWD-Basket-...
Leo – 9 month old male Cross-Breed
Leo is a 9 month old male Cross-Breed, expected to grow into a medium to large-sized adult. He is currently fostered in Bulgaria and is ready to travel to the United Kingdom once t...
Telix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic A...
Leo Cancer Care secures $65M to advance upright radiotherapy system as company preps for IPO
Medical technology company Leo Cancer Care closed a $65 million series D financing round to scale its radiotherapy solution, which uses groundbreaking upright treatment technology.
RXO, Inc. (RXO) Presents at Deutsche Bank's Chicago Industrials Summit Transcript
Serbia - Ognjen-Petronijevic-ex-Vrsac-joins-Leotar
KK-Leotar-Trebinje-Division-I-agreed-terms-with-26-year-old-Serbian-guard-Ognjen-Petronijevic-195cm-2000-agency-Octagon-Europe-for-new-2026-27-season-He-played-last-season-at-KK-Vr...
Leo Cancer Care secures $65M to advance upright radiotherapy system as company preps for IPO
Medical technology company Leo Cancer Care closed a $65 million series D financing round to scale its radiotherapy solution, which uses groundbreaking upright treatment technology.
Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nod
Leo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a rare skin disease drug from Tanabe Pharma that's awaiting an approval...
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.